The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose vaccine trial participants to the pathogen, but it may become an option if ongoing trials hit a snag.
The British drug maker has started phase 2 and 3 trials of a vaccine, and will need a certain number of participants to become infected in the course of their normal lives to achieve a reliable reading from the study over the next few months.
Read the latest updates in our dedicated coronavirus section.
So-called human challenge trials have been discussed as an alternative option by scientists, whereby vaccinated volunteers are infected intentionally.
“We are running against time. We are seeing already in Europe the disease is declining... Very soon the disease intensity will be low, and it will become difficult, so we have to move very quickly,” Soriot told an online press briefing.
“If the disease gets to a very low level, maybe challenge studies will have to be considered. But we felt it’s too early today to do that,” he added.